整理 | GLP1减重宝典内容团队 礼来加拿大公司（Eli Lilly Canada）宣布，ZEPBOUND™ KwikPen®（替尔泊肽注射液）现已在加拿大正式上市。这款每周一次的注 射剂，为患有肥胖或超重的成年患者提供了新的慢性体重管理方案。该药物已获得加拿大卫生部批准，用于与健康饮食和规律运动相结 合的长期体重控制。 激活双重激素受体的新机制 ZEPBOUND™通过同时激活两种激素受体——GIP（葡萄糖依赖性促胰岛素多肽）和GLP-1（胰高血糖素样肽-1）——来调节食欲和代 谢。这是加拿大首个也是唯一一个被批准用于长期体重管理的双受体激动剂，具有减重和维持体重的双重作用。 ZEPBOUND™适用于体重指数（BMI）为30及以上的成人，或BMI在27至30之间但患有与体重相关疾病的患者，例如高血压、血脂异 常、2型糖尿病、睡眠呼吸暂停症或心血管疾病。 应对日益严峻的健康挑战 "肥胖是一种严重的慢性疾病，对健康有广泛影响。"礼来加拿大公司总经理兼总裁Mathilde Merlet表示，"如果不加干预，它会引发多 种慢性病，增加医疗系统负担，降低劳动生产率，甚至导致残疾。ZEPBOUND™的推出，是我们在肥胖 ...

Core Insights - Demand for Eli Lilly's GLP-1 medicines, Mounjaro and Zepbound, remains robust, generating $6.15 billion in Q1 2025, accounting for approximately 48% of total revenues [1][8] - Sales of Mounjaro and Zepbound rebounded in Q1 2025 due to new international market launches and improved supply, despite lower-than-expected sales in the second half of 2024 [2][8] - The company anticipates Q2 2025 sales of $4.5 billion for Mounjaro and $3.1 billion for Zepbound, driven by deeper market penetration [3][8] Company Performance - Eli Lilly's broader portfolio, including oncology and immunology drugs, continues to show steady growth, with contributions from recently launched products [4] - The company's shares have outperformed the industry year-to-date, indicating strong market performance [7] Industry Context - The U.S. obesity market is projected to reach $100 billion by 2030, with Eli Lilly and Novo Nordisk as the primary competitors [5] - Novo Nordisk's semaglutide medicines, Ozempic and Wegovy, compete directly with Lilly's offerings, contributing significantly to Novo's revenues [5] - Other companies, such as Viking Therapeutics, are also advancing in the obesity space with new investigational drugs [6] Valuation and Estimates - Eli Lilly's shares are currently trading at a P/E ratio of 29.66, above the industry average of 15.16, but below its five-year mean of 34.54 [10] - The bottom-line estimate for 2025 remains at $21.92, while the estimate for 2026 has slightly decreased from $30.91 to $30.84 [11]

Group 1 - Tesla officially enters the Indian market with the opening of its first experience center in Mumbai on July 15, having imported vehicles and related products worth $1 million [1] - Greenland Group and DeepBlue Technology have established a joint venture, "Greenland DeepBlue AI Medical Technology Company," aimed at promoting the DeepBlue-MR-v1 medical model, which ranks first in complex medical reasoning evaluations [1] Group 2 - Mafengwo's personalized travel planning product "AI Roadbook" is now available to all users, featuring tools for restaurant reservations and real-time translation, enhancing the travel experience from planning to execution [2] - NielsenIQ and Gaode Cloud have signed a strategic cooperation agreement to launch "Channel Cloud Map," a retail intelligence solution that integrates real-time store data and professional verification for comprehensive market coverage [3] Group 3 - The first "Suning.com Cup" Honor of Kings national super league has been launched, with over 2,000 teams competing across 40 cities, aiming to establish 100 e-sports experience zones by 2025 [4] - The D20 Global Design Dean Summit was held in Hangzhou, focusing on the integration of design and technology, and promoting the establishment of AI design talent standards through the "D20 Declaration" [5] Group 4 - LeEco has been ordered to pay over 10.07 million yuan due to enforcement actions, highlighting ongoing financial difficulties faced by the company [6][7] - Nestlé's offices in France were searched as part of an investigation into allegations of using illegal filtration systems in their bottled water products [8] Group 5 - The Shanghai Cooperation Organization signed 12 digital economy cooperation projects, focusing on cross-border e-commerce and smart cities, during the 2025 Digital Economy Forum [9] - Beijing has launched a comprehensive service platform to support enterprises in the "Belt and Road" initiative, providing one-stop services in policy communication, financial connectivity, and talent exchange [10] - The adjustment of the national medical insurance drug list and the commercial health insurance innovative drug list has officially started, aiming to enhance the multi-level medication guarantee system [11] - The Chinese Foreign Ministry announced ongoing simplification of visa application procedures to facilitate smoother travel for foreign visitors to China [12]

Core Viewpoint - Eli Lilly and Company's stock has declined 15.7% over the past year due to a first-quarter earnings miss, guidance cut, and positive developments at rival Novo Nordisk, alongside broader economic challenges [1][10]. Group 1: Company Performance - Lilly's cardiometabolic division is its strongest segment, driven by the success of GLP-1 therapies Mounjaro and Zepbound, which together account for approximately 48% of total revenues [3][4]. - Despite slower-than-expected sales in the second half of 2024, Mounjaro and Zepbound saw a resurgence in the first quarter of 2025 due to new international market launches and improved supply [5][6]. - Lilly anticipates continued growth for Mounjaro and Zepbound through expanded international uptake and deeper market penetration in the U.S. [6][7]. Group 2: Product Pipeline and Future Growth - Lilly has secured approvals for several new therapies, including Omvoh, Jaypirca, Ebglyss, and Kisunla, which are expected to contribute to revenue growth in 2025 [10][11]. - The company is also advancing its pipeline in obesity, diabetes, and cancer, with several key mid and late-stage data readouts expected this year [12]. - Lilly is diversifying beyond GLP-1 drugs by expanding into cardiovascular, oncology, and neuroscience areas, including recent M&A deals to enhance its pipeline [13]. Group 3: Competitive Landscape - The obesity market is projected to reach $100 billion by 2030, with Lilly and Novo Nordisk currently dominating the space [14]. - Mounjaro and Zepbound face competition from Novo Nordisk's semaglutide products and emerging candidates from companies like Amgen and Viking Therapeutics [15][17]. - Other pharmaceutical companies are also entering the obesity market, which could challenge Lilly's and Novo Nordisk's market positions [18]. Group 4: Financial Outlook - Lilly expects 2025 revenues to be between $58 billion and $61 billion, indicating a year-over-year growth of approximately 32% [30]. - The company's stock has increased by over 400% in the past five years, primarily due to successful drug launches and a strong pipeline [29]. - Despite a high valuation with a price/earnings ratio of 29.54 compared to the industry average of 15.04, Lilly's stock is trading below its five-year mean [23].

长江商报消息 ●长江商报记者 徐阳 亚太股份（002284.SZ）发展劲头十足。 7月8日晚，亚太股份公告称，公司预计归属于上市公司股东的净利润（以下简称"净利润"）同比增长 81.97%—101.13%，扣除非经常性损益后的净利润（以下简称"扣非净利润"）同比增长84.56%— 106.28%。 作为国内汽车制动系统行业的龙头企业，亚太股份始终聚焦主业，坚持走自主创新之路，并积极拓展国 内、国外市场，助力公司实现高质量发展。 长江商报记者梳理发现，亚太股份年内总共披露了6个定点公告，累计金额36.8亿元，进一步巩固和提 高了公司的市场竞争力。 2025上半年预盈超1.9亿 据了解，亚太股份作为一级零部件系统供应商可以为客户提供包括底盘系统部件、汽车电子、线控制动 以及轮毂电机等产品与技术，公司的线控制动系统和线控转向可为整车智能化、自动驾驶提供最佳的执 行系统方案。 2025年，亚太股份业绩继续保持高增长。 半年度业绩预告显示，1—6月，公司预计净利润为1.9亿—2.1亿元，比上年同期增长81.97%— 101.13%；扣非净利润为1.7亿—1.9亿元，比上年同期增长84.56%—106.28%。 2025 ...

Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growt ...

Core Viewpoint - Jim Gaffigan has successfully lost weight using the drug Mounjaro, which is a brand name for tirzepatide, a medication initially approved for type 2 diabetes treatment that also aids in weight loss [4][6]. Group 1: Drug Information - Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates both GLP-1 and GIP hormones to help regulate blood sugar levels [4]. - The FDA approved tirzepatide in May 2022 for improving blood sugar control in type 2 diabetes patients, and in November 2023, it was approved for weight loss in adults with obesity or overweight [4]. - In the SURMOUNT-5 clinical trial, participants treated with tirzepatide lost an average of 50.3 pounds (approximately 22.8 kg), with an average weight reduction of 20.2% [4]. Group 2: Personal Experience - Gaffigan initially had low expectations about the drug's effectiveness due to previous negative experiences shared by others [6]. - He struggled with weight gain for most of his adult life and faced challenges such as a slowing metabolism and knee pain [6]. - After consulting with his doctor, he decided to try the medication, which led to significant weight loss and improved health [6][8]. Group 3: Lifestyle Changes - Gaffigan maintains his health by walking in New York City and tracking his steps with an Apple Watch, despite not exercising extensively [8]. - His weight loss has positively impacted his family life, as his wife appreciates his improved health [8].

Economic Outlook - Analysts forecast an average of 5% year-over-year (YOY) earnings growth for S&P 500 companies, indicating a mix of optimism and caution among investors [1][2] - Growth expectations have recently increased, especially for tech stocks, although the growth rate is expected to be slower than the previous year [2] Investment Strategies - Companies are awaiting clarity on tariffs, which complicates accurate forecasting for analysts and investors [3] - Large-cap, blue-chip companies are recommended as a strategy to navigate uncertainty due to their strong balance sheets, cash flow, and pricing power [3] Company-Specific Insights Alphabet Inc. (GOOGL) - Current stock price is $174.12 with a 12-month price forecast of $200.00, representing a 14.86% upside [5] - In Q1, revenue increased by 12% YOY and earnings per share (EPS) rose by 49% YOY, with significant growth in Google Cloud [6] - The company is investing in future growth areas such as autonomous driving, AI chip development, and quantum computing, alongside a $70 billion share buyback [7] Eli Lilly and Company (LLY) - Current stock price is $781.06 with a 12-month price forecast of $1,011.61, indicating a 29.52% upside [9] - The company has a strong position in the GLP-1 drug category and is developing an oral version of its treatment [10] - LLY stock is projected to see earnings growth of over 34% in the next year, with a consensus price target of $1,012 [11] JPMorgan Chase & Co. (JPM) - Current stock price is $282.81 with a 12-month price forecast of $276.80, suggesting a slight downside of 2.13% [13] - The bank has achieved a total return of over 256% in the last five years, benefiting from higher interest rates [14] - Expected earnings growth for JPM is 7.2%, which is above the S&P average, and the company offers a dividend yield of 1.92% [15]

Core Viewpoint - Hims & Hers Health, Inc. is facing significant challenges, including an 18% decline in stock price over the past month, primarily due to the termination of its collaboration with Novo Nordisk and ongoing legal scrutiny regarding its compounded drug offerings [1][2][3]. Company Developments - The termination of the collaboration with Novo Nordisk in June 2025 has resulted in Hims & Hers losing direct access to Wegovy, a popular GLP-1 weight-loss drug [1][3]. - Hims & Hers aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, despite current challenges [3]. - The company reported over $225 million in revenue from GLP-1 products in 2024, indicating some success in this segment [6]. Regulatory and Legal Context - Novo Nordisk cited Hims & Hers' alleged failure to comply with laws regarding compounded drugs and deceptive marketing practices as reasons for ending the collaboration [2]. - The FDA's removal of semaglutide from the drug shortage list has impacted Hims & Hers, as it indicates sufficient supply to meet demand, reducing the justification for compounded versions [5]. - Legal scrutiny is focused on the legality of mass-producing compounded versions of GLP-1 drugs now that the official shortage is over [6][7]. Market Implications - Analysts from Morgan Stanley have noted an increased focus on the legal and business implications for Hims & Hers, particularly in light of Eli Lilly's lawsuits against compounding pharmacies [7][12]. - Experts suggest that compounding pharmacies should cease large-scale production of GLP-1 drugs once the shortage ends, although there may be cases for compounding under specific regulations [8][9]. - The ongoing legal cases could take 2 to 3 years to resolve, impacting the operational landscape for Hims & Hers [12]. Strategic Moves - Hims & Hers announced an agreement to acquire ZAVA, a digital health platform in Europe, which will expand its presence in the UK and enter new markets such as Germany, France, and Ireland [13].

整理 | GLP1减重宝典内容团队 这些言论是周三在JAMA的一篇评论文章中发表的，由世卫组织官员Jeremy Farrar、Francesco Branca和Francesca Celletti撰写。 在文章中，专家们称肥胖是一个"大流行"的公共卫生问题， 影响全球10多亿人，几乎每个国家的病例都在增加。2019年，肥胖相关的非传染性 疾病夺走了500万人的生命。到 2030 年，全球肥胖相关成本可能达到 3 万亿美元 。 据世界卫生组织称，GLP-1受体激动剂目前正以高度医疗化的方式使用。 医疗保健系统需要制定更全面的解决方案，重点关注健康促进、疾病 预防和政策干预。 世界卫生组织官员认为， GLP-1 肥胖疗法的迅速崛起为该行业和医疗保健系统提供了对抗肥胖大流行的有力武器，但目前 的部署方式有可能无法实现这一目标。 在此背景下，GLP-1 受体激动剂的兴起和日益普及可能会对肥胖护理产生"变革性"影响，为各国卫生系统提供有效的药物治疗选择。 "然而，单独的药物治疗不足以解决肥胖危机，"世卫组织官员写道，并补充说，医疗保健系统必须采取整体应对措施，"确保普遍提供预防、治 疗和管理疾病的服务，使之易于获得、负 ...